secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amylyx Pharmaceuticals, Inc. (AMLX)
CIK:        0001658551
Form:       8-K
Filed at:   2026-08-20T21:28:20+00:00
Accession:  0001193125-26-359418
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amylyx prices $471.7M equity offering to fund avexitide launch
--------------------------------------------------------------

- 14,090,000 shares at $35.50/share; 30-day option for 2,113,500 more.
- Net proceeds ~$471.7M (~$542.5M if option fully exercised).
- Proceeds to fund potential U.S. launch of avexitide, R&D, working capital.
- Offering expected to close Aug 21, 2026; underwriters: Leerink, Morgan Stanley, Guggenheim, LifeSci.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658551/000119312526359418/0001193125-26-359418-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658551/000119312526359418/d179247d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-359418

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer